Newly developed retatrutide, a combined-action drug targeting both GLP-1 and GIP receptors, is generating considerable interest within the medical community. Preliminary clinical studies have shown impressive decreases in overall weight and gains in health markers for people with overweight. Experts believe this unique approach may signify a si… Read More